Cu(I)/TF–BiphamPhos-catalyzed asymmetric 1,3-dipolar cycloaddition of azomethine ylides with dimethyl itaconate and 2-methyleneglutarate

Hai-Yan Taoa, Zhao-Lin Hea, Yang Yanga and Chun-Jiang Wang*ab
aCollege of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China. E-mail: cjwang@whu.edu.cn; Fax: +86-27-68754067
bState Key Laboratory of Elemento-organic Chemistry, Nankai University, Tianjin, 300071, China

Received 7th February 2014 , Accepted 25th March 2014

First published on 27th March 2014


Abstract

Catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides with dimethyl itaconate and 2-methyleneglutarate was realized with the Cu(I)/TF–BiphamPhos complex as the catalyst for the efficient construction of pyrrolidine derivatives bearing one unique all carbon-quaternary and two tertiary stereogenic centers. The current catalytic system exhibited excellent diastereoselectivity (> 20[thin space (1/6-em)]:[thin space (1/6-em)]1), good enantioselectivity (88–>99% ee) and broad substrate scope under mild conditions.


Introduction

Highly functionalized pyrrolidines bearing multiple stereogenic centers are one of the most important heterocyclic motifs, which are widely observed in many natural alkaloids and marketed pharmaceuticals.1 Enantiomerically enriched pyrrolidine derivatives were also successfully employed as organocatalysts, chiral ligands and also useful building blocks in organic synthesis.2 Among the developed methodologies for the optically active pyrrolidines syntheses, catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides with electron-deficient olefins is one of the most powerful and atom-economical carbon–carbon bond-forming reaction3 that provides an efficient approach and diversity-oriented synthesis (DOS)4 for the construction of a variety of structurally and stereochemically diversified pyrrolidines from the readily-available starting materials. Since the first example on the catalytic asymmetric 1,3-dipolar cycloaddition of in situ-generated azomethine ylide reported in 2002,5 much endeavours have been made to developing catalytic asymmetric protocols for 1,3-dipolar cycloaddition, in which various types of chiral metal complexes and chiral organocatalysts have been successfully employed as the efficient catalysts to afford stereochemically diversified pyrrolidine derivatives with moderate to high enantio-/diastereoselectivities in the last decade.6 Although various electron-deficient alkenes have been utilized as the dipolarophiles in azomethine ylide-involved 1,3-dipolar cycloaddition, most of them are limited to maleates, fumarates, maleimides, acrylates, nitroalkenes, and vinyl phenyl sulfones.3,6 Dimethyl itaconate or 2-methyleneglutarate, which were commonly used as substrates in asymmetric hydrogenation reactions,7 have been seldom employed as dipolarophiles in the asymmetric 1,3-dipolar cycloaddition of azomethine ylides. To the best of our knowledge, only one racemic example has been reported involving itaconate as the dipolarophile so far.8 In view of the simultaneous formation of one unique all carbon-quaternary9 and two tertiary stereogenic centers in the pyrrolidine rings, it is a great challenge to control both diastereoselectivity and enantioselectivity in dimethyl itaconate and 2-methyleneglutarate-involved asymmetric 1,3-dipolar cycloaddition reaction (Scheme 1). In continuation of the interest in construction of biologically active and enantioenriched pyrrolidines,10 we herein reported the first catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides to dimethyl itaconate or 2-methyleneglutarate with excellent levels of diastereoselectivity and enantioselectivity. The current methodology could diversify the existing methodology for the facile access to the biologically active pyrrolidine derivatives.
image file: c4ra02195a-s1.tif
Scheme 1 Catalytic asymmetric 1,3-dipolar cycloaddition of azomethine ylides using dimethyl itaconate as the dipolarophiles.

Results and discussion

Initially, N-benzylidene glycine methyl ester 2a was selected as the 1,3-dipole precursor and dimethyl itaconate 1 as the dipolarophile to investigate the stereoselective control in the presence of the combined metal salts and chiral ligand TF–BiphamPhos,10a and the representative results are listed in Table 1. The 1,3-dipolar cycloaddition reaction occurred smoothly and finished in 4 h with 3 mol% AgOAc/(S)-TF–BiphamPhos (L1) as the catalyst and 15 mol% Et3N as base in dichloromethane at room temperature, the desired cycloadduct 3a bearing a unique all carbon-quaternary and two tertiary stereogenic centers was obtained as a single isomer in good yield with exclusive diastereoselectivity (dr > 20[thin space (1/6-em)]:[thin space (1/6-em)]1) and moderate enantioselectivity of 40% ee (Table 1, entry 1), which indicated that dimethyl itaconate could be applied as an effective dipolarophile in the azomethine ylide-involved 1,3-dipolar cycloaddition reaction for the synthesis of highly functionalized pyrrolidine derivatives. Encouraged by these promising results, we further pursue to improve the enantioselective control of this reaction. To our gratification, the enantioselectivity was greatly increased to 73% ee with maintained high diastereoselectivity for this cycloaddition by switching the metal precursor from AgOAc into Cu(CH3CN)4BF4 (entry 2), which revealed that the corresponding active intermediate generated from chiral Cu(I)/TF–BiphamPhos coordinated by in situ-formed azomethine ylide has more favourable interactions with the dipolarophile itaconate and hence afforded higher enantioselectivity control than that from Ag(I)/TF–BiphamPhos complex. Next, Cu(CH3CN)4BF4 was selected as the metal precursor for subsequent survey of other TF–BiphamPhos ligands with different substituents either on the phenyl ring of diaryl phosphine group or on the chiral backbone. It was found that the enantioselectivity in this 1,3-dipolar cycloaddition was greatly affected by both the electronic effect and steric effect of the chiral ligand: deteriorative effect on the enantioselectivity was observed when the phenyl ring on the phosphorous atom of ligand (L1) was replaced by xylyl group (L2) or cyclohexyl group (L4) (entries 3 and 5). Similar enantioselective control were observed with chiral ligand bearing the strongly electron-withdrawing 3,5-bis(trifluoromethyl)-phenyl group (L3) (entry 4). Further ligand variant showed that TF–BiphamPhos (L5) was the most effective chiral ligand providing 3a exclusively in 92% yield and 81% ee within 8 h (Table 1, entry 6). Next, the solvent effect on this annulation was also investigated, CH2Cl2 was revealed to be the best solvent in terms of the yield and enantioselectivity while polar solvents such as methanol and acetonitrile were less effective for this transformation (Table 1, entries 6–10). 90% ee with full conversion and exclusive diastereoselectivity was realized through reducing the reaction temperature to −20 °C with DCM as the solvent (Table 1, entry 12). Thus, the optimized reaction conditions were established as 3 mol% of Cu(CH3CN)4BF4/L5 and 15 mol% Et3N in DCM at −20 °C.
Table 1 Catalytic asymmetric 1,3-dipolar cycloaddition of imino ester 2a with dimethyl itaconate 1aa

image file: c4ra02195a-u1.tif

Entry L [M] Solvent T (°C) Time (h) Yieldb (%) eec (%)
a All reactions were carried out with 0.23 mmol of 1a and 0.35 mmol of 2a in 2 mL solvent.b Isolated yield.c Dr was determined by the crude 1H NMR and ee was determined by HPLC analysis.
1 L1 AgOAc DCM rt 12 91 40
2 L1 Cu(CH3CN)4BF4 DCM rt 8 90 73
3 L2 Cu(CH3CN)4BF4 DCM rt 8 79 60
4 L3 Cu(CH3CN)4BF4 DCM rt 8 81 74
5 L4 Cu(CH3CN)4BF4 DCM rt 8 52 65
6 L5 Cu(CH3CN)4BF4 DCM rt 8 92 81
7 L5 Cu(CH3CN)4BF4 Et2O rt 12 79 73
8 L5 Cu(CH3CN)4BF4 MeCN rt 12 31 75
9 L5 Cu(CH3CN)4BF4 EtOAc rt 8 78 77
10 L5 Cu(CH3CN)4BF4 MeOH rt 12 90 65
11 L5 Cu(CH3CN)4BF4 DCM −10 12 88 83
12 L5 Cu(CH3CN)4BF4 DCM −20 20 81 90


Under the optimized reaction conditions, we investigated the substrate scope of this 1,3-dipolar cycloaddition of dimethyl itaconate 1a with respect to azomethine ylide. As shown in Table 2, a series of representative imino esters derived from various aromatic aldehydes and glycinate reacted smoothly with dimethyl itaconate 1a leading to the corresponding adducts (3a–3j) in good yields (76–95%), excellent diastereoselectivity (dr > 20[thin space (1/6-em)]:[thin space (1/6-em)]1) and high enantio-selectivities (88–>99%) at −20 °C within 18–24 h. It appears that the electronic property of the substituents on the aryl rings has little effect on the stereoselectivities. Imino esters bearing electron-neutral group (Table 2, entry 1), electron-deficient group (entries 2–4), and electron-rich groups (entries 5–10) on the aryl rings all worked well in this cycloaddition. On the contrary, the substituent pattern of the aromatic rings has some effect on the enantioselectivities. A little lower enantioselectivities was observed for meta-chloro and meta-methyl-substituted imino esters 2d and 2g (entries 4 and 7). Remarkably, comparable excellent diastereoselectivity and enantio-selectivity were still obtained for the sterically hindered ortho-chloro, ortho-methyl, ortho-methoxyl-substituted imino esters 2c, 2f and 2i (entries 3, 6 and 9). However, no cycloaddition occurred when the less reactive alkyl substituted imino ester was tested under the optimal reaction conditions (entry 12). Notably, α-methyl substituted imino ester 3k derived from alanine was also tolerated in this transformation, affording the desired pyrrolidines bearing one all-carbon quaternary and one nitrogen-substituted quaternary stereogenic centers in good yield with the maintained exclusive diastereoselectivity (> 20[thin space (1/6-em)]:[thin space (1/6-em)]1) and excellent enantioselectivity (93% ee) (entry 11). The absolute configuration of the cycloadduct 3c was determined to be (2R,4S,5S) by X-ray analysis (Fig. 1), and the relative and absolute configuration of all other cycloadducts was tentatively assigned by analogy.

Table 2 Substrate scope of Cu(I)/L5-catalyzed asymmetric 1,3-dipolar cycloaddition of various imino esters 2 with dimethyl itaconate 1aa

image file: c4ra02195a-u2.tif

Entry R1 R2 3 Yieldb (%) eec (%)
a All reactions were carried out with 0.23 mmol of 1a and 0.35 mmol of 2 in 2 mL CH2CI2. CuBF4 = Cu(CH3CN)4BF4.b Isolated yield.c Dr was determined by the crude 1H NMR and ee was determined by HPLC analysis.
1 Ph (2a) H 3a 81 90
2 p-CI-C6H4 (2b) H 3b 85 91
3 o-CI-C6H4 (2c) H 3c 86 93
4 m-CI-C6H4 (2d) H 3d 90 88
5 p-Me-C6H4 (2e) H 3e 95 >99
6 o-Me-C6H4 (2f) H 3f 92 94
7 m-Me-C6H4 (2g) H 3g 93 89
8 p-MeO-C6H4 (2h) H 3h 81 92
9 o-MeO-C6H4 (2i) H 3i 76 94
10 m-MeO-C6H4 (2j) H 3j 88 90
11 Ph (2k) Me 3k 82 93
12 Bu (2I) H



image file: c4ra02195a-f1.tif
Fig. 1 ORTEP representation of the cycloadduct (2R,4S,5S)-3c at 15% probability for the drawing of thermal ellipsoids.

To further investigate the generality of the dipolarophile for this 1,3-dipolar cycloaddition reaction, dimethyl 2-methyleneglutarate was also tested under the optimal reaction conditions. As shown in Fig. 2, dimethyl 2-methyleneglutarate 1b has also proven to be excellent dipolarophile in this annulation producing the corresponding cycloadducts 3l and 3m in high yields with high diastereoselectivities and excellent enantioselectivities.


image file: c4ra02195a-f2.tif
Fig. 2 The results of 1,3-dipolar cycloaddition of azomethine ylides with dimethyl 2-methyleneglutarate as the dipolarophile.

The stereochemical results of this annulation can be explained through the proposed transition state in Fig. 3. Azomethine ylide is coordinated to the chiral copper(I) metallic center in such way to form tetracoordinated active species,6k,11 subsequently followed by the annulation with dimethyl itaconate from the Si face (C[double bond, length as m-dash]N) of the ylide giving rise to the cycloadduct 3a in endo-configuration. The carbonyl group connected to unsaturated C[double bond, length as m-dash]C bond in dimethyl itaconate could coordinate more preferentially with the Cu(I) center than another one, which may benefit for stabilizing the negatively charged oxygen atom. It cannot eliminate the possible hydrogen-bonding interaction between the carbonyl group in the dipolarophile and the NH2 group in the ligand TF–BiphamPhos.12


image file: c4ra02195a-f3.tif
Fig. 3 Proposed transition state.

Conclusions

In conclusion, we reported a Cu(I)/TF–BiphamPhos-catalyzed asymmetric 1,3-dipolar cycloaddition reaction of azomethine ylides with dimethyl itaconate and 2-methyleneglutarate to provide a series of highly substituted pyrrolidines bearing one unique all-carbon quaternary and two tertiary stereogenic centers for the first time. Excellent stereoselective control and broad substrate scope were uniformly observed for various azomethine ylides. The easy availability of the substrates and the bioactive importance of the enantioenriched pyrrolidine derivatives make the present methodology particularly interesting in organic synthesis. Further studies on the mechanistic details and its application are ongoing in this laboratory.

Experimental

General

All reactions were carried out using standard Schlenk techniques unless specified other otherwise. The degassed dry solvents are used throughout each experiment. 1H NMR spectra were recorded on a VARIAN Mercury 300 MHz spectrometer in CDCl3. Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The data are reported as (s = single, d = double, t = triple, q = quartet, m = multiple or unresolved, brs = broad single, coupling constant(s) in Hz, integration). 13C NMR spectra were recorded on a VARIAN Mercury 75 MHz spectrometer in CDCl3. Chemical shifts are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard. Commercially obtained reagents were used without further purification. All reactions were monitored by TLC with silica gel-coated plates. Diastereomeric ratios were determined from crude 1H NMR. Enantiomeric excesses were determined by HPLC, using a chiralpak IA, a chiralpak AS-H, chiralpak AD-H, or chiralcel OD-H column with hexane and i-PrOH as solvents. Dimethyl 2-methyleneglutarate13 and imino esters,10a were prepared according to the literature procedure. Chiral ligands L1–L5 were prepared according to the literature procedure reported by us.10a

Synthetic details

General procedure for asymmetric 1,3-dipolar cycloaddition of azomethine ylides with dimethyl itaconate catalyzed by Cu(CH3CN)4BF4/(S)-TF–BiphamPhos (L5) complex. Under argon atmosphere, (S)-TF–BiphamPhos L5 (6.1 mg, 0.0076 mmol) and Cu(CH3CN)4BF4 (2.2 mg, 0.0069 mmol) were dissolved in 2 mL of DCM. After stirring at room temperature for about 0.5 h, the reaction mixture was dropped to −20 °C. Then, imino ester substrate (0.35 mmol), Et3N (0.03 mmol) and dimethyl itaconate (0.23 mmol) were added sequentially. Once starting material was consumed (monitored by TLC), the mixture was filtered through celite and the filtrate was concentrated to dryness. The product was purified by column chromatography to give the corresponding cycloadduct, which was then directly analysed by HPLC to determine the enantiomeric excess.
(2R,4S,5R)-Dimethyl 4-(2-methoxy-2-oxoethyl)-5-phenylpyrrolidine-2,4-dicarboxylate (3a). The title compound was prepared according to the general procedure as described above in 81% yield (62 mg) as white solid. M.p. 147–148 °C; [α]25D = +16.2 (c 1.09, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.33–7.23 (m, 5H), 4.09 (s, 1H), 4.05 (dd, J1 = 6.3 Hz, J2 = 15.9 Hz, 1H), 3.85 (s, 3H), 3.65 (s, 3H), 3.25 (s, 3H), 3.11 (d, J = 16.8 Hz, 1H), 3.06–3.01 (m, 1H), 2.58 (br, 1H), 2.51 (d, J = 16.8 Hz, 1H), 2.28 (dd, J1 = 9.6 Hz, J2 = 13.8 Hz, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 173.9, 172.8, 171.4, 137.1, 128.2, 126.5, 72.4, 58.7, 56.0, 52.1, 51.6, 51.4, 40.2, 39.6; IR (KBr) ν 2954, 2923, 2844, 2396, 1736, 1460, 1437, 1359, 1117, 1082, 1005, 926, 889, 669 cm−1. HRMS calcd for C17H21NO6 + H+: 336.1447, found 336.1442. The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralpak IA, i-propanol–hexane = 30/70, flow rate 1.0 mL min−1, λ = 220 nm); tr = 13.96 and 18.29 min.
(2R,4S,5R)-Dimethyl 5-(4-chlorophenyl)-4-(2-methoxy-2-oxoethyl)pyrrolidine-2,4-dicarboxylate (3b). The title compound was prepared according to the general procedure as described above in 85% yield (72 mg) as white solid. M.p. 167–168 °C; [α]25D = +31.4 (c 1.10, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.30 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 4.07 (s, 1H), 4.01 (dd, J1 = 6.3 Hz, J2 = 9.3 Hz, 1H), 3.84 (s, 3H), 3.66 (s, 3H), 3.29 (s, 3H), 3.09 (d, J = 16.8 Hz, 1H), 3.03 (dd, J1 = 6.3 Hz, J2 = 13.8 Hz, 1H), 2.51 (d, J = 17.1 Hz, 1H), 2.27 (dd, J1 = 9.3 Hz, J2 = 13.8 Hz, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 173.8, 172.5, 171.2, 136.1, 133.7, 128.3, 128.0, 71.3, 58.4, 55.9, 52.1, 51.6, 51.5, 40.1, 39.0; IR (KBr) ν 2952, 2399, 1736, 1490, 1438, 1354, 1094, 1010, 669 cm−1. HRMS calcd for C17H20ClNO6 + H+: 370.1057, found 370.1062. The product was analyzed by HPLC to determine the enantiomeric excess: 91% ee (Chiralpak AS-H, i-propanol–hexane = 40/60, flow rate 1.0 mL min−1, λ = 220 nm); tr = 7.63 and 11.66 min.
(2R,4S,5S)-Dimethyl 5-(2-chlorophenyl)-4-(2-methoxy-2-oxoethyl)pyrrolidine-2,4-dicarboxylate (3c). The title compound was prepared according to the general procedure as described above in 86% yield (73 mg) as white solid. M.p. 160–161 °C; [α]25D = +24.7 (c 1.28, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.47–7.45 (m, 1H), 7.37–7.35 (m, 1H), 7.26–7.20 (m, 3H), 4.79 (s, 1H), 4.03 (m, 1H), 3.84 (s, 3H), 3.65 (s, 3H), 3.32 (d, J = 17.7 Hz, 1H), 3.26 (s, 3H), 3.11 (dd, J1 = 6.9 Hz, J2 = 13.8 Hz, 1H), 2.63 (d, J = 17.4 Hz, 1H), 2.26 (dd, J1 = 9.0 Hz, J2 = 13.8 Hz, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 173.8, 172.7, 171.6, 135.6, 133.6, 129.5, 129.0, 127.9, 126.7, 66.4, 58.5, 56.7, 52.1, 51.6, 51.5, 40.7, 39.5; IR (KBr) ν 2954, 2923, 2849, 1739, 1437, 1361, 1120, 1080, 1037, 1000, 668 cm−1. HRMS calcd for C17H20ClNO6 + H+: 370.1057, found 370.1060. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AS-H, i-propanol–hexane = 40/60, flow rate 1.0 mL min−1, λ = 220 nm); tr = 6.48 and 13.44 min.
(2R,4S,5R)-Dimethyl 5-(3-chlorophenyl)-4-(2-methoxy-2-oxoethyl)pyrrolidine-2,4-dicarboxylate (3d). The title compound was prepared according to the general procedure as described above in 90% yield (76 mg) as white solid. M.p. 163–164 °C; [α]25D = +30.4 (c 1.60, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.26 (m, 3H), 7.16 (m, 1H), 4.05–3.99 (m, 2H), 3.85 (s, 3H), 3.66 (s, 3H), 3.31 (s, 3H), 3.10 (d, J = 17.1 Hz, 1H), 3.04 (dd, J1 = 6.3 Hz, J2 = 13.8 Hz, 1H), 2.51 (d, J = 16.8 Hz, 1H), 2.26 (dd, J1 = 9.6 Hz, J2 = 13.8 Hz, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 173.8, 172.5, 171.2, 139.7, 134.1, 129.5, 128.3, 126.9, 124.9, 71.5, 58.5, 56.0, 52.2, 51.7, 51.5, 40.2, 39.0; IR (KBr) ν 2954, 2928, 2853, 2399, 1738, 1598, 1575, 1437, 1360, 1118, 1081, 1002, 872, 668 cm−1. HRMS calcd for C17H20ClNO6 + H+: 370.1057, found 370.1058. The product was analyzed by HPLC to determine the enantiomeric excess: 88% ee (Chiralpak IA, i-propanol–hexane = 30/70, flow rate 1.0 mL min−1, λ = 220 nm); tr = 18.79 and 28.93 min.
(2R,4S,5R)-Dimethyl 4-(2-methoxy-2-oxoethyl)-5-(p-tolyl)-pyrrolidine-2,4-dicarboxylate (3e). The title compound was prepared according to the general procedure as described above in 95% yield (76 mg) as white solid. M.p. 155–156 °C; [α]25D = +32.2 (c 1.39, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.12 (m, 4H), 4.02–3.98 (m, 2H), 3.84 (s, 3H), 3.64 (s, 3H), 3.29 (s, 3H), 3.09 (d, J = 17.1 Hz, 1H), 3.03 (dd, J1 = 6.0 Hz, J2 = 14.1 Hz, 1H), 2.47 (d, J = 16.8 Hz, 1H), 2.32 (s, 3H), 2.27–2.22 (m, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 174.1, 173.0, 171.5, 137.9, 133.7, 129.0, 126.4, 72.4, 58.7, 55.9, 52.2, 51.7, 51.5, 40.2, 39.8, 21.0; IR (KBr) ν 2994, 2953, 2854, 1737, 1606, 1515, 1436, 1359, 1323, 1205, 1117, 1079, 1020, 897, 811 cm−1. HRMS calcd for C18H23NO6 + H+: 350.1604, found 350.1611. The product was analyzed by HPLC to determine the enantiomeric excess: >99% ee (Chiralpak AD-H, i-propanol–hexane = 30/70, flow rate 1.0 mL min−1, λ = 220 nm); tr = 15.04 and 23.32 min.
(2R,4S,5R)-Dimethyl 4-(2-methoxy-2-oxoethyl)-5-(o-tolyl)-pyrrolidine-2,4-dicarboxylate (3f). The title compound was prepared according to the general procedure as described above in 92% yield (74 mg) as white solid. M.p. 136–137 °C; [α]25D = +1.8 (c 1.29, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.37–7.15 (m, 4H), 4.48 (s, 2H), 4.05–3.99 (m, 1H), 3.84 (s, 3H), 3.65 (s, 3H), 3.27 (s, 3H), 3.13 (d, J = 16.5 Hz 1H), 3.07 (dd, J1 = 7.2 Hz, J2 = 14.1 Hz, 1H), 2.56 (d, J = 16.5 Hz, 1H), 2.30 (s, 3H), 2.26 (dd, J1 = 9.0 Hz, J2 = 13.5 Hz, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 174.0, 173.0, 171.3, 136.0, 135.8, 130.6, 127.7, 126.0, 125.7, 67.0, 58.8, 56.7, 51.7, 51.5, 40.7, 39.7, 20.0; IR (KBr) ν 2954, 2928, 1738, 1458, 1437, 1357, 1319, 1118, 1077, 1005, 668 cm−1. HRMS calcd for C18H23NO6 + H+: 350.1604, found 350.1608. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AD-H, i-propanol–hexane = 30/70, flow rate 1.0 mL min−1, λ = 220 nm); tr = 6.31 and 10.75 min.
(2R,4S,5R)-Dimethyl 4-(2-methoxy-2-oxoethyl)-5-(m-tolyl)-pyrrolidine-2,4-dicarboxylate (3g). The title compound was prepared according to the general procedure as described above in 93% yield (75 mg) as white solid. M.p. 132–133 °C; [α]25D = +10.2 (c 1.29, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.24–7.18 (m, 1H), 7.11–7.03 (m, 3H), 4.04–3.99 (m, 2H), 3.85 (s, 3H), 3.65 (s, 3H), 3.28 (s, 3H), 3.10 (d, J = 17.1 Hz, 1H), 3.04 (dd, J1 = 5.7 Hz, J2 = 13.8 Hz, 1H); 2.48 (d, J = 16.8 Hz, 1H), 2.34 (s, 3H), 2.26 (dd, J1 = 9.9 Hz, J2 = 13.8 Hz, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 173.9, 173.0, 171.5, 137.9, 136.6, 129.0, 128.2, 127.2, 123.7, 72.5, 58.7, 56.0, 52.2, 51.7, 51.4, 40.2, 39.8, 21.3; IR (KBr) ν 2952, 2923, 2852, 1735, 1435, 1358, 1201, 1176, 1122, 1078, 1003, 879, 795, 781, 699 cm−1. HRMS calcd for C18H23NO6 + H+: 350.1604, found 350.1610. The product was analyzed by HPLC to determine the enantiomeric excess: 89% ee (Chiralpak AD-H, i-propanol–hexane = 30/70, flow rate 1.0 mL min−1, λ = 220 nm); tr = 14.35 and 31.06 min.
(2R,4S,5R)-Dimethyl 4-(2-methoxy-2-oxoethyl)-5-(4-methoxyphenyl) pyrrolidine-2,4-dicarboxylate (3h). The title compound was prepared according to the general procedure as described above in 81% yield (68 mg) as white solid. M.p. 148–149 °C; [α]25D = +25.9 (c 1.19, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.16 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 4.03 (s, 1H), 3.99 (dd, J1 = 12.3 Hz, J2 = 18.6 Hz, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.65 (s, 3H), 3.30 (s, 3H), 3.08 (d, J = 17.1 Hz, 1H), 3.02 (dd, J1 = 6.3 Hz, J2 = 14.1 Hz, 1H), 2.47 (d, J = 17.1 Hz, 1H), 2.26 (dd, J1 = 9.6 Hz, J2 = 13.8 Hz, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 174.0, 173.0, 171.5, 159.4, 129.0, 127.7, 113.6, 72.0, 58.6, 55.9, 55.1, 52.2, 51.6, 51.5, 40.2, 39.6; IR (KBr) ν 2954, 2928, 1736, 1612, 1515, 1438, 1112, 1035, 669 cm−1. HRMS calcd for C18H23NO7 + H+: 366.1553, found 366.1551. The product was analyzed by HPLC to determine the enantiomeric excess: 92% ee (Chiralpak AS-H, i-propanol–hexane = 40/60, flow rate 1.0 mL min−1, λ = 220 nm); tr = 6.49 and 13.04 min.
(2R,4S,5R)-Dimethyl 4-(2-methoxy-2-oxoethyl)-5-(2-methoxyphenyl) pyrrolidine-2,4-dicarboxylate (3i). The title compound was prepared according to the general procedure as described above in 76% yield (64 mg) as white solid. M.p. 142–143 °C; [α]25D = +4.4 (c 1.10, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.26–7.21 (m, 2H), 6.95–6.85 (m, 2H), 4.59 (s, 1H), 4.00 (dd, J1 = 6.0 Hz, J2 = 9.6 Hz, 1H), 3.83 (s, 3H), 3.82 (s, 3H), 3.64 (s, 3H), 3.27 (s, 3H), 3.20 (d, J = 17.7 Hz, 1H), 3.04 (dd, J1 = 6.6 Hz, J2 = 14.1 Hz, 1H), 2.53 (d, J = 17.4 Hz, 1H), 2.24 (dd, J1 = 9.9 Hz, J2 = 13.8 Hz, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 173.9, 173.4, 172.0, 156.9, 128.9, 126.7, 124.8, 120.3, 110.4, 65.3, 58.8, 56.1, 55.2, 52.1, 51.6, 51.5, 40.5, 40.4; IR (KBr) ν 2999, 2952, 2923, 2852, 1736, 1601, 1579, 1493, 1437, 1358, 1324, 1246, 1204, 1176, 1115, 1079, 1026, 900, 759 cm−1. HRMS calcd for C18H23NO7 + H+: 366.1553, found 366.1560. The product was analyzed by HPLC to determine the enantiomeric excess: 94% ee (Chiralpak AD-H, i-propanol–hexane = 30/70, flow rate 1.0 mL min−1, λ = 220 nm); tr = 10.74 and 24.50 min.
(2R,4S,5R)-Dimethyl 4-(2-methoxy-2-oxoethyl)-5-(3-methoxyphenyl) pyrrolidine-2,4-dicarboxylate (3j). The title compound was prepared according to the general procedure as described above in 88% yield (74 mg) as white solid. M.p. 137–138 °C; [α]25D = +17.9 (c 1.13, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.24–7.22 (m, 1H), 6.84–6.81 (m, 3H), 4.04–3.99 (m, 2H), 3.84 (s, 3H), 3.80 (s, 3H), 3.66 (s, 3H), 3.30 (s, 3H), 3.13 (d, J = 17.1 Hz, 1H), 3.04 (dd, J1 = 6.0 Hz, J2 = 13.8 Hz, 1H), 2.49 (d, J = 17.1 Hz, 1H), 2.27 (dd, J1 = 9.6 Hz, J2 = 13.8 Hz, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 174.0, 172.8, 171.5, 159.5, 138.8, 129.3, 118.8, 113.4, 112.6, 72.4, 58.8, 56.1, 55.1, 52.2, 51.7, 51.5, 40.3, 39.6; IR (KBr) ν 2954, 2925, 2844, 1737, 1602, 1492, 1456, 1437, 1360, 1112, 1077, 1049, 998, 699, 666 cm−1. HRMS calcd for C18H23NO7 + H+: 366.1553, found 366.1558. The product was analyzed by HPLC to determine the enantiomeric excess: 90% ee (Chiralcel OD-H, i-propanol–hexane = 30/70, flow rate 1.0 mL min−1, λ = 220 nm); tr = 15.82 and 28.07 min.
(2R,4S,5R)-Dimethyl 4-(2-methoxy-2-oxoethyl)-2-methyl-5-phenylpyrrolidine-2,4-dicarboxylate (3k). The title compound was prepared according to the general procedure as described above in 82% yield (66 mg) as white solid. M.p. 124–125 °C; [α]25D = +25.0 (c 1.83, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.33–7.19 (m, 5H), 4.15 (s, 1H), 3.86 (s, 3H), 3.64 (s, 3H), 3.42 (d, J = 14.1 Hz, 1H), 3.28 (s, 3H), 3.07 (d, J = 17.1 Hz, 1H), 2.41 (d, J = 17.1 Hz, 1H), 1.85 (d, J = 14.1 Hz, 1H), 1.52 (s, 3H); 13C NMR (CDCl3, TMS, 75 MHz) δ 177.1, 173.0, 171.5, 136.3, 128.4, 128.3, 126.5, 71.6, 65.0, 57.7, 52.5, 51.7, 51.4, 48.4, 40.5, 29.0; IR (KBr) ν 2950, 2397, 1735, 1487, 1359, 1084, 1008, 673 cm−1. HRMS calcd for C18H23NO6 + H+: 350.1604, found 350.1605. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralcel AD-H, i-propanol–hexane = 20/80, flow rate 1.0 mL min−1, λ = 220 nm); tr = 8.67 and 9.82 min.
(2R,4R,5R)-Dimethyl 5-(4-chlorophenyl)-4-(3-methoxy-3-oxopropyl)pyrrolidine-2,4-dicarboxylate (3l). The title compound was prepared according to the general procedure as described above in 85% yield (75 mg) as white solid. M.p. 155–156 °C; [α]25D = +28.1 (c 1.05, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.29 (d, J = 8.4 Hz), 7.23 (d, J = 8.4 Hz), 4.10 (s, 1H), 4.03 (dd, J1 = 6.0 Hz, J2 = 9.0 Hz, 1H), 3.84 (s, 3H), 3.68 (s, 3H), 3.27 (s, 3H), 2.72 (dd, J1 = 6.0 Hz, J2 = 13.2 Hz, 1H), 2.36–2.26 (m, 3H), 2.15 (dd, J1 = 9.6 Hz, J2 = 13.5 Hz, 1H), 1.86–1.80 (m, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 174.0, 173.1, 172.9, 136.7, 133.6, 128.2, 128.1, 72.7, 58.4, 52.2, 51.7, 51.5, 37.5, 31.0, 30.8; IR (KBr) ν 2997, 2953, 2918, 2844, 1732, 1489, 1435, 1377, 1304, 1203, 1176, 1117, 1089, 1013, 986, 834, 694 cm−1. HRMS calcd for C18H22ClNO6 + H+: 384.1214, found 384.1219. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak AS-H, i-propanol–hexane = 40/60, flow rate 1.0 mL min−1, λ = 220 nm); tr = 6.93 and 10.29 min.
(2R,4R,5R)-Dimethyl 4-(3-methoxy-3-oxopropyl)-5-(4-methoxyphenyl)pyrrolidine-2,4-dicarboxylate (3m). The title compound was prepared according to the general procedure as described above in 81% yield (71 mg) as white solid. M.p. 140–141 °C; [α]25D = +25.0 (c 1.83, CHCl3); 1H NMR (CDCl3, TMS, 300 MHz) δ 7.18 (d, J = 8.4 Hz, 2H), 6.85 (d, J = 8.4 Hz, 2H), 4.07 (s, 1H), 4.02 (dd, J1 = 6.3 Hz, J2 = 9.9 Hz, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.67 (s, 3H), 3.28 (s, 3H), 2.70 (dd, J1 = 5.7 Hz, J2 = 13.2 Hz, 1H), 2.36–2.25 (m, 3H), 2.14 (dd, J1 = 9.3 Hz, J2 = 12.9 Hz, 1H), 1.82–1.79 (m, 1H); 13C NMR (CDCl3, TMS, 75 MHz) δ 174.1, 173.3, 173.2, 159.2, 129.7, 127.7, 113.5, 73.3, 58.5, 58.3, 55.1, 52.2, 51.6, 51.4, 38.0, 31.1, 31.0; IR (KBr) ν 2997, 2953, 2847, 2360, 2342, 1736, 1698, 1685, 1600, 1578, 1260, 1161, 1027, 835, 669 cm−1. HRMS calcd for C19H25NO7 + H+: 380.1709, found 380.1706. The product was analyzed by HPLC to determine the enantiomeric excess: 99% ee (Chiralpak AS-H, i-propanol–hexane = 40/60, flow rate 1.0 mL min−1, λ = 220 nm); tr = 8.68 and 13.41 min.

Acknowledgements

We gratefully acknowledge financial support from the 973 Program (2011CB808600), NSFC (21172176) and Hubei Province NSF (ZRZ0273).

Notes and references

  1. (a) S. G. Pyne, A. S. Davis, N. J. Gates, J. Nicole, J. P. Hartley, K. B. Lindsay, T. Machan and M. Tang, Synlett, 2004, 2670 CrossRef CAS PubMed; (b) L. M. Harwood and R. J. Vickers, in Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry Toward Heterocycles and Natural Products, ed. A. Padwa and W. Pearson, Wiley & Sons, New York, 2002 Search PubMed.
  2. (a) Privileged Chiral Ligands and Catalysts, ed. Q.-L. Zhou, Wiley-VCH, Weinheim, 2011 Search PubMed; (b) A. Berkessel and H. Gröger, Asymmetric Organocatalysis: From Biomimetic Concepts to Applications in Asymmetric Synthesis, Wiley-VCH, Weinheim 2004 Search PubMed.
  3. For recent reviews about 1,3-dipolar cycloaddition reactions of azomethine ylides, see: (a) J. Yu, F. Shi and L.-Z. Gong, Acc. Chem. Res., 2011, 44, 1156 CrossRef CAS PubMed; (b) J. Adrio and J. C. Carretero, Chem. Commun., 2011, 47, 6784 RSC; (c) B. Engels and M. Christl, Angew. Chem., Int. Ed., 2009, 48, 7968 CrossRef CAS PubMed; (d) L. M. Stanley and M. P. Sibi, Chem. Rev., 2008, 108, 2887 CrossRef CAS PubMed; (e) M. Alvarez-Corral, M. Munoz-Dorado and I. Rodrıguez-Garcıa, Chem. Rev., 2008, 108, 3174 CrossRef CAS PubMed; (f) M. Bonin, A. Chauveau and L. Micouin, Synlett, 2006, 2349 CrossRef CAS; (g) C. Nájera and J. M. Sansano, Angew. Chem., Int. Ed., 2005, 44, 6272 CrossRef PubMed.
  4. (a) S. L. Schreiber, Science, 2000, 287, 1964 CrossRef CAS; (b) C. Chen, X. Li and S. L. Schreiber, J. Am. Chem. Soc., 2003, 125, 10174 CrossRef CAS PubMed.
  5. (a) J. M. Longmire, B. Wang and X. Zhang, J. Am. Chem. Soc., 2002, 124, 13400 CrossRef CAS PubMed; (b) A. S. Gothelf, K. V. Gothelf, R. G. Hazell and K. A. Jørgensen, Angew. Chem., Int. Ed., 2002, 41, 4236 CrossRef CAS.
  6. For recent examples, see: (a) A. Awata and T. Arai, Chem.–Eur. J., 2012, 18, 8278 CrossRef CAS PubMed; (b) L. Wang, X.-M. Shi, W.-P. Dong, L.-P. Zhu and R. Wang, Chem. Commun., 2013, 49, 3458 RSC; (c) L. He, X.-H. Chen, D.-N. Wang, S.-W. Luo, W.-Q. Zhang, J. Yu, L. Ren and L.-Z. Gong, J. Am. Chem. Soc., 2011, 133, 13504 CrossRef CAS PubMed; (d) X.-H. Chen, W.-Q. Zhang and L.-Z. Gong, J. Am. Chem. Soc., 2008, 130, 5652 CrossRef CAS PubMed; (e) W. Zeng, G.-Y. Chen, Y.-G. Zhou and Y.-X. Li, J. Am. Chem. Soc., 2007, 129, 750 CrossRef CAS PubMed; (f) W. Zeng and Y.-G. Zhou, Org. Lett., 2005, 7, 5055 CrossRef CAS PubMed; (g) J.-W. Shi, M.-X. Zhao, Z.-Y. Lei and M. Shi, J. Org. Chem., 2008, 73, 305 CrossRef CAS PubMed; (h) T. Arai, A. Mishiro, N. Yokoyama, K. Suzuli and H. Sato, J. Am. Chem. Soc., 2010, 132, 5338 CrossRef CAS PubMed; (i) C. Nájera, M. D. G. Retamosa and J. Sansano, Angew. Chem., Int. Ed., 2008, 47, 6055 CrossRef PubMed; (j) C. Chen, X. Li and S. L. Schreiber, J. Am. Chem. Soc., 2003, 125, 10174 CrossRef CAS PubMed; (k) X.-X. Yan, Q. Peng, Y. Zhang, K. Zhang, W. Hong, X.-L. Hou and Y.-D. Wu, Angew. Chem., Int. Ed., 2006, 45, 1979 CrossRef CAS PubMed; (l) S. Cabrera, R. Gómez Arrayás and J. C. Carretero, J. Am. Chem. Soc., 2005, 127, 16394 CrossRef CAS PubMed; (m) S. Saito, T. Tsubogo and S. Kobayashi, J. Am. Chem. Soc., 2007, 129, 5364 CrossRef CAS PubMed; (n) Y. Yamashita, T. Imaizumi and S. Kobayashi, Angew. Chem., Int. Ed., 2011, 50, 4893 CrossRef CAS PubMed; (o) H. Y. Kim, J.-Y. Li, S. Kim and K. Oh, J. Am. Chem. Soc., 2011, 133, 20750 CrossRef CAS PubMed; (p) J. Hernández-Toribio, S. Padilla, J. Adrio and J. C. Carretero, Angew. Chem., Int. Ed., 2012, 51, 8854 CrossRef PubMed; (q) R. Narayan, J. O. Bauer, C. Strohmann, A. P. Antonchick and H. Waldmann, Angew. Chem., Int. Ed., 2013, 52, 12892 CrossRef CAS PubMed; (r) S. Watanabe, A. Tada, Y. Tokoro and S.-i. Fukuzawa, Tetrahedron Lett., 2014, 55, 1306 CrossRef CAS PubMed.
  7. (a) W. Tang and X. Zhang, Chem. Rev., 2003, 103, 3029 CrossRef CAS PubMed; (b) H. U. Blaser, C. Malan, B. Pugin, F. Spindler, H. Steiner and M. Studer, Adv. Synth. Catal., 2003, 345, 103 CrossRef CAS PubMed.
  8. Y. S. Or, C. Wang, X. Peng, L. Ying and Y.-L. Qiu, US Pat., 20100074863, 2010.
  9. (a) Quaternary Stereocenters: Challenges and Solution for Organic Synthesis, ed. J. Christoffers and A. Baro, WILEY-VCH, Weinheim, 2005 Search PubMed; (b) B. M. Trost and C. Jiang, Synthesis, 2006, 369 CrossRef CAS PubMed.
  10. (a) C.-J. Wang, G. Liang, Z.-Y. Xue and F. Gao, J. Am. Chem. Soc., 2008, 130, 17250 CrossRef CAS PubMedC.-J. Wang, Z.-Y. Xue, G. Liang and Z. Lu, Chem. Commun., 2009, 2905 RSC; (b) G. Liang, M.-C. Tong and C.-J. Wang, Adv. Synth. Catal., 2009, 351, 3101 CrossRef CAS PubMed; (c) Z.-Y. Xue, T.-L. Liu, Z. Lu, H. Huang, H.-Y. Tao and C.-J. Wang, Chem. Commun., 2010, 46, 1727 RSC; (d) G. Liang, M.-C. Tong, H.-Y. Tao and C.-J. Wang, Adv. Synth. Catal., 2010, 352, 1851 CrossRef CAS PubMed; (e) T.-L. Liu, Z.-Y. Xue, H.-Y. Tao and C.-J. Wang, Org. Biomol. Chem., 2011, 9, 1980 RSC; (f) Z.-Y. Xue, X. Fang and C.-J. Wang, Org. Biomol. Chem., 2011, 9, 3622 RSC; (g) T.-L. Liu, Z.-L. He, H.-Y. Tao and C.-J. Wang, Chem.–Eur. J., 2012, 18, 8042 CrossRef CAS PubMed; (h) T.-L. Liu, Z.-L. He, H.-Y. Tao, Y.-P. Cai and C.-J. Wang, Chem. Commun., 2011, 47, 2616 RSC; (i) Q.-H. Li, M.-C. Tong, J. Li, H.-Y. Tao and C.-J. Wang, Chem. Commun., 2011, 47, 11110 RSC; (j) T.-L. Liu, Z.-L. He and C.-J. Wang, Chem. Commun., 2011, 47, 9600 RSC; (k) H.-L. Teng, H. Huang, H.-Y. Tao and C.-J. Wang, Chem. Commun., 2011, 47, 5494 RSC; (l) H.-L. Teng, F.-L. Luo, H.-Y. Tao and C.-J. Wang, Org. Lett., 2011, 13, 5600 CrossRef CAS PubMed; (m) T.-L. Liu, Z.-L. He, Q.-H. Li, H.-Y. Tao and C.-J. Wang, Adv. Synth. Catal., 2011, 353, 1713 CrossRef CAS PubMed; (n) M.-C. Tong, J. Li, H.-Y. Tao, Y.-X. Li and C.-J. Wang, Chem.–Eur. J., 2011, 17, 12922 CrossRef CAS PubMed; (o) D. Yan, Q. Li and C.-J. Wang, Chin. J. Chem., 2012, 30, 2714 CAS; (p) Q.-H. Li, Z.-Y. Xue, H.-Y. Tao and C.-J. Wang, Tetrahedron Lett., 2012, 53, 3650 CrossRef CAS PubMed; (q) T.-L. Liu, Z.-L. He, H.-Y. Tao and C.-J. Wang, Chem.–Eur. J., 2012, 18, 8042 CrossRef CAS PubMed; (r) H.-L. Teng, H. Huang and C.-J. Wang, Chem.–Eur. J., 2012, 18, 16214 CrossRef PubMed; (s) K. Liu, H.-L. Teng, L. Yao, H.-Y. Tao and C.-J. Wang, Org. Lett., 2013, 15, 2250 CrossRef CAS PubMed; (t) Z.-L. He, H.-L. Teng and C.-J. Wang, Angew. Chem., Int. Ed., 2013, 52, 2934 CrossRef CAS PubMed.
  11. (a) H. Y. Kim, H.-J. Shih, W. E. Knabe and K. Oh, Angew. Chem., Int. Ed., 2009, 48, 7420 CrossRef CAS PubMed; (b) C. Nájera, M. D. G. Retamosa, J. M. Sansano, A. Cózar and F. P. Cossío, Tetrahedron: Asymmetry, 2008, 19, 2913 CrossRef PubMed.
  12. For review on N-H effect in asymmetric synthesis, see: (a) B. Zhao, Z. Han and K. L. Ding, Angew. Chem., Int. Ed., 2013, 53, 4744 CrossRef PubMed; (b) Z.-Y. Xue, Q.-H. Li, H.-Y. Tao and C.-J. Wang, J. Am. Chem. Soc., 2011, 133, 11757 CrossRef CAS PubMed; (c) M.-C. Tong, J. Li, H.-Y. Tao, Y.-X. Li and C.-J. Wang, Chem.–Eur. J., 2011, 17, 12922 CrossRef CAS PubMed; (d) M. Wang, C.-J. Wang and Z. Lin, Organometallics, 2012, 31, 7870 CrossRef CAS; (e) P. Fackler, C. Berthold, F. Voss and T. Bach, J. Am. Chem. Soc., 2010, 132, 15911 CrossRef CAS PubMed.
  13. Z.-C. Duan, X.-P. Hu, J. Deng, S.-B. Yu, D.-Y. Wang and Z. Zheng, Tetrahedron: Asymmetry, 2009, 20, 588 CrossRef CAS PubMed.

Footnote

Electronic supplementary information (ESI) available: Experimental section, crystal data for (2R,4S,5S)-3c: C17H20ClNO6, Mr = 369.79, T = 296 K, orthorhombic, space group P212121, a = 9.8397(12), b = 10.1420(13), c = 17.897(2) Å, V = 1786.1(4) Å3, Z = 4, 11[thin space (1/6-em)]885 reflections measured, 3273 unique (Rint = 0.0332) which were used in all calculations. The final wR2 = 0.0870 (all data), Flack χ = 0.03(6). CCDC 985571. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c4ra02195a

This journal is © The Royal Society of Chemistry 2014
Click here to see how this site uses Cookies. View our privacy policy here.